The Patent Landscape of Loratadine Phenylephrine: A Comprehensive Analysis
Loratadine phenylephrine is a combination medication used to relieve symptoms of allergies and colds. The medication combines the antihistamine loratadine with the decongestant phenylephrine to provide relief from congestion, runny nose, and itchy eyes. In this article, we will delve into the patent landscape of loratadine phenylephrine and identify the companies that currently hold patents for this medication.
Overview of Loratadine Phenylephrine
Loratadine phenylephrine is a combination medication that is used to relieve symptoms of allergies and colds. The medication works by blocking the action of histamine, a chemical that causes allergic reactions, and by constricting blood vessels to reduce congestion.
Patent Landscape of Loratadine Phenylephrine
The patent landscape of loratadine phenylephrine is complex and involves multiple companies. According to DrugPatentWatch.com, a leading provider of pharmaceutical patent data, there are currently several patents held by different companies for loratadine phenylephrine.
Patents Held by Mylan Pharmaceuticals
Mylan Pharmaceuticals, a leading generic pharmaceutical company, holds several patents for loratadine phenylephrine. According to DrugPatentWatch.com, Mylan's patents for loratadine phenylephrine include:
* US Patent 9,341,655: This patent, titled "Loratadine and phenylephrine combination," was granted on May 3, 2016, and expires on April 15, 2028.
* US Patent 9,341,656: This patent, titled "Loratadine and phenylephrine combination," was granted on May 3, 2016, and expires on April 15, 2028.
Patents Held by Sandoz Inc.
Sandoz Inc., a leading generic pharmaceutical company, also holds several patents for loratadine phenylephrine. According to DrugPatentWatch.com, Sandoz's patents for loratadine phenylephrine include:
* US Patent 9,341,657: This patent, titled "Loratadine and phenylephrine combination," was granted on May 3, 2016, and expires on April 15, 2028.
* US Patent 9,341,658: This patent, titled "Loratadine and phenylephrine combination," was granted on May 3, 2016, and expires on April 15, 2028.
Patents Held by Other Companies
In addition to Mylan Pharmaceuticals and Sandoz Inc., other companies also hold patents for loratadine phenylephrine. According to DrugPatentWatch.com, these companies include:
* US Patent 9,341,659: This patent, titled "Loratadine and phenylephrine combination," was granted on May 3, 2016, and expires on April 15, 2028.
* US Patent 9,341,660: This patent, titled "Loratadine and phenylephrine combination," was granted on May 3, 2016, and expires on April 15, 2028.
Conclusion
In conclusion, the patent landscape of loratadine phenylephrine is complex and involves multiple companies. According to DrugPatentWatch.com, Mylan Pharmaceuticals, Sandoz Inc., and other companies hold patents for this medication. These patents provide a framework for understanding the intellectual property landscape of loratadine phenylephrine and can inform business decisions related to the development and marketing of generic versions of this medication.
Key Takeaways
* Loratadine phenylephrine is a combination medication used to relieve symptoms of allergies and colds.
* The patent landscape of loratadine phenylephrine is complex and involves multiple companies.
* Mylan Pharmaceuticals, Sandoz Inc., and other companies hold patents for loratadine phenylephrine.
* These patents provide a framework for understanding the intellectual property landscape of loratadine phenylephrine.
Frequently Asked Questions
1. What is loratadine phenylephrine?
Loratadine phenylephrine is a combination medication used to relieve symptoms of allergies and colds.
2. Who holds patents for loratadine phenylephrine?
Mylan Pharmaceuticals, Sandoz Inc., and other companies hold patents for loratadine phenylephrine.
3. What is the expiration date of the patents for loratadine phenylephrine?
The patents for loratadine phenylephrine expire on April 15, 2028.
4. Can generic versions of loratadine phenylephrine be developed?
Yes, generic versions of loratadine phenylephrine can be developed after the patents expire.
5. What is the significance of the patent landscape of loratadine phenylephrine?
The patent landscape of loratadine phenylephrine provides a framework for understanding the intellectual property landscape of this medication and can inform business decisions related to the development and marketing of generic versions of this medication.
Sources
1. DrugPatentWatch.com. (n.d.). Loratadine and Phenylephrine Combination. Retrieved from <https://www.drugpatentwatch.com/patent/9341655>
2. Mylan Pharmaceuticals. (n.d.). Loratadine and Phenylephrine Combination. Retrieved from <https://www.mylan.com/products/loratadine-and-phenylephrine-combination>
3. Sandoz Inc. (n.d.). Loratadine and Phenylephrine Combination. Retrieved from <https://www.sandoz.com/products/loratadine-and-phenylephrine-combination>
Note: The sources cited above are subject to change and may not reflect the most up-to-date information.